North America Insulin Pen Market Size & Share 2025 - 2034

North America Insulin Pen Market Size

The North America insulin pen market was valued at USD 3.5 billion in 2024 and is projected to grow from USD 3.9 billion in 2025 to USD 9.2 billion by 2034, expanding at a CAGR of 10.1% according to the latest report published by Global Market Insights Inc.

The growth of the North American insulin pen market is driven by several factors, including the rising prevalence of diabetes across the region, increasing technological advancements in insulin pens, a shift toward self-administration and home healthcare, and growing government and public health initiatives. Key players in this market include Novo Nordisk, Eli Lilly and Company, Sanofi, and Becton, Dickinson and Company.
 

The market value increased from USD 2.6 billion in 2021 to USD 3.2 billion in 2023. The North American insulin pen market is primarily driven by the rising prevalence of diabetes across the region. For instance, according to the Centers for Disease Control and Prevention, in the U.S., 38.4 million people of all ages, representing 11.6% of the total population, were living with diabetes.
 

Among them, 38.1 million adults aged 18 and older accounted for 14% of all U.S. adults. This surge in the patient population underscores the demand for scalable and accessible insulin delivery technologies. This increasing healthcare burden is fueling the need for timely and accurate treatment solutions, thereby accelerating the growth of the North American insulin pen market across the region.
 

Government-led initiatives and public health programs are significantly influencing the North America insulin pen market by improving access to diabetes care. The rising prevalence of diabetes has prompted authorities to implement comprehensive strategies focused on prevention, early diagnosis, and affordable treatment. In the U.S., the National Diabetes Prevention Program (National DPP) exemplifies this approach by fostering partnerships between public and private organizations to deliver evidence-based, cost-effective interventions aimed at reducing the burden of prediabetes and type 2 diabetes. These programs prioritize equitable healthcare by ensuring access to affordable insulin, advanced delivery technologies such as insulin pens, and integrated care models.
 

An insulin pen is a medical device designed to deliver insulin to individuals with diabetes in a convenient and precise manner. It contains an insulin cartridge, a dial for dose adjustment, and a disposable needle for injection.
 

North America Insulin Pen Market Trends

• Technological advancements in insulin pens have progressed significantly, introducing features such as smart dose tracking, bluetooth connectivity, and digital integration with mobile apps. These innovations allow users to monitor insulin usage, receive reminders, and share data with healthcare providers, improving treatment accuracy and adherence.
   
• Additionally, advancements such as AI-powered dosing recommendations, integration with continuous glucose monitors (CGMs), and cloud-based health platforms for real-time data sharing are driving greater adoption of insulin pens.
   
• For example, Apidra SoloStar is a prefilled disposable insulin pen designed to deliver rapid-acting insulin glulisine, typically administered around mealtimes to control blood sugar spikes. It provides precise dosing and portability, making it a convenient option for people managing diabetes.
   
• Moreover, manufacturers are continuously refining pen designs to enhance dosing accuracy, user comfort, and ease of use. Modern pens now feature simplified mechanisms, ergonomic grips, and prefilled cartridges to minimize user error and support consistent insulin administration.
   

North America Insulin Pen Market Analysis

Based on type, the North America insulin pen market is divided into reusable and disposable insulin pens. The reusable insulin pens segment accounted for 37.7% of the market in 2024 due to their durability, ability to use multiple cartridges, and long-term cost efficiency compared to disposable pens. The segment is expected to exceed USD 3.5 billion by 2034, growing with the fastest CAGR of 10.2% during the forecast period.
 

• Reusable insulin pens are devices that deliver insulin and can be used multiple times with interchangeable insulin cartridges. Unlike disposable insulin pens, which are prefilled and discarded after a single use, reusable pens provide a more economical and environmentally friendly solution.
   
• These pens have a durable outer casing and a mechanism that allows users to insert a new insulin cartridge once the previous one is empty. Users set the required dose using a dial, and the pen delivers insulin through a needle. After each use, only the needle is discarded, while the pen and cartridge remain in use until the insulin runs out.
   
• Additionally, reusable insulin pens drive market growth because they are cost-effective, sustainable, and offer added value to consumers with features such as memory functions, dosage tracking, and digital connectivity.
   
• For example, NovoPen, developed by Novo Nordisk, is a reusable insulin pen designed to deliver precise doses of insulin with ease and reliability. Models such as NovoPen 6 and NovoPen Echo Plus include digital dose memory, enabling users to track their last injection time and amount. These smart features improve treatment adherence and support better diabetes management.
   
• Moreover, due to their affordability, practicality, precision, and sustainability, reusable insulin pens are increasingly preferred by diabetes care practitioners, which accelerates market growth.
   

Based on the indication, the North America insulin pen market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. The type 1 diabetes segment dominated the market in 2024 with a revenue of USD 2 billion.
 

• The rising prevalence of type 1 diabetes is driving demand for innovative insulin pens across the region. Type 1 diabetes, an autoimmune disorder that destroys insulin-producing beta cells, leads to insufficient insulin production and requires lifelong insulin therapy, often beginning in childhood or adolescence.
   
• For instance, in 2021, approximately 2 million individuals in the U.S. were living with type 1 diabetes, including about 304,000 children and adolescents, highlighting the significant and growing patient population that requires diabetes management.
   
• Insulin pens are essential for managing type 1 diabetes because they provide a convenient, accurate, and easy way to deliver insulin multiple times a day. Their design simplifies the injection process, reduces dosing errors, and enhances adherence to treatment regimens critical for individuals requiring intensive insulin therapy for life.
   
• Additionally, modern insulin pens offer advanced features such as dose memory, ergonomic designs, and smart connectivity, further improving user experience and supporting better treatment outcomes.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on distribution channels, North America insulin pen market is classified into hospital pharmacies, retail pharmacies, and e-commerce. The retail pharmacies segment is expected to reach USD 3.4 billion by 2034.
 

• Retail pharmacies have emerged as the fastest-growing distribution channel for insulin pens due to their accessibility and strong patient engagement. As healthcare delivery shifts toward convenience, consumers increasingly seek immediate access to diabetes care products. Retail pharmacies serve as a convenient solution for purchasing insulin pens, receiving device education, and managing prescriptions.
   
• Additionally, retail pharmacies offer both disposable and reusable insulin pens and often collaborate with manufacturers on discount programs, insurance coverage, and patient education.
   
• Further, pharmacists play a critical role in guiding patients on device selection, dosage, and proper usage, acting as an essential touchpoint for diabetes care. Retail pharmacies drive growth in the insulin pen market by enhancing product visibility, building consumer trust, and improving accessibility.
   

The U.S North America insulin pen market was valued at USD 2.4 billion and USD 2.6 billion in 2021 and 2022, respectively. In 2024, the market size reached USD 3.1 billion from USD 2.8 billion in 2023.
 

• The increasing prevalence of both type 1 and type 2 diabetes in the U.S. is significantly driving the demand for insulin pens.
   
• For instance, the rising diabetes burden in the U.S. is illustrated in the graphic, which shows that about 98 million American adults, more than 1 in 3, have prediabetes, and over 80% are unaware of it. This alarming statistic highlights the growing need for early intervention and effective diabetes management tools.
   
• The U.S. leads in technological innovation, offering smart insulin pens, which is estimated to reach USD 1.9 billion by 2032, with bluetooth connectivity, dose tracking, and integration with mobile apps for better diabetes management. These features improve adherence and patient convenience.
   

Canada insulin pen market accounted for USD 384.4 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The rising prevalence of diabetes in Canada is significantly increasing the demand for insulin pens. With growing cases of both type 1 and type 2 diabetes, the need for consistent and efficient insulin delivery has become critical.
   
• For instance, according to Diabetes Canada, an estimated 5.8 million individuals in Canada are living with diabetes, representing nearly 15% of the population. Of these, over 4 million are diagnosed, accounting for 10%. These figures highlight the urgent need to expand access to advanced diabetes care technologies and devices to support early detection, improve patient outcomes, and reduce long-term complications.
   
• Therefore, as the diabetes burden continues to rise in Canada, the demand for insulin pens is growing rapidly.
   
• Increasing awareness among healthcare providers and patients about the benefits of insulin pens, such as ease of use, precision, and reduced injection pain, has further accelerated their adoption over traditional syringes.
   

North America Insulin Pen Market Share

• Major players such as Novo Nordisk, Eli Lilly, Sanofi, Ypsomed, and Becton Dickinson & Company hold a strong position in the North American insulin pen market. Their dominance is driven by extensive product portfolios, robust distribution networks, regulatory compliance, and continuous innovation. Collectively, these top five companies account for 58% of the market share.
   
• Outside hospitals and clinics, there is a growing preference for home-based insulin pens, creating new opportunities for both established and emerging players. Consumers increasingly favor portable, user-friendly pens that offer accurate dosing, privacy, and convenience. This trend is further supported by innovations such as bluetooth-enabled smart pens, mobile app integration, and cloud-based dose tracking, which make insulin therapy more personalized and efficient.
   
• New entrants in the insulin pen market are adopting diverse strategies to gain market share. These include developing next-generation smart pens with features such as dose memory, real-time glucose syncing, and AI-powered dosing recommendations. Many are also forming strategic partnerships with digital health platforms, pharmacies, and healthcare providers to improve accessibility, reduce costs, and enhance patient adherence.
   

North America Insulin Pen Market Companies

Few of the prominent players operating in the North America insulin pen industry include:

• Becton, Dickinson and Company 
• Biocon Biologics
• Eli Lilly and Company
• Gan & Lee Pharmaceuticals
• Haselmeier
• Julphar 
• Medtronic
• Medmix
• Novo Nordisk
• Owen Mumford
• Sanofi
• Valeritas
• Ypsomed
   
• Novo Nordisk

Novo Nordisk is a global leader in diabetes care, offering advanced insulin pens designed for precision, ease of use, and patient adherence. Its focus on smart pen technology and digital integration enhances treatment accuracy and supports personalized diabetes management.
 

• Medtronic 

Medtronic contributes to the insulin pen market through its focus on smart diabetes technologies, offering connected solutions that enhance insulin delivery precision and patient monitoring. Its approach integrates digital tools to support personalized and data-driven diabetes care.
 

• Owen Mumford 

Owen Mumford is a medical device company known for its expertise in injection and drug delivery systems, including insulin pens. It focuses on developing ergonomic, easy-to-use pen devices that support safe and accurate insulin administration, with a strong emphasis on patient comfort and usability.
 

North America Insulin Pen Industry News:

• In August 2020, Medtronic announced the acquisition of Companion Medical, the maker of InPen, the FDA-cleared smart insulin pen system integrated with a diabetes management app in the U.S. This strategic move expanded Medtronic’s capabilities to support individuals using multiple daily injections (MDI), enhancing its diabetes care ecosystem and simplifying insulin dosing decisions.
   

The North America insulin pen market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Reusable insulin pens
• Disposable insulin pens       

Market, By Indication

• Type 1 diabetes
• Type 2 diabetes
• Gestational diabetes

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following countries:

• North America
  • U.S.
  • Canada